Items where authors include "Vernon, J"
Article
Freeman, J, Vernon, J orcid.org/0000-0002-0072-9294, Pilling, S et al. (7 more authors) (2020) Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study. European Journal of Clinical Microbiology & Infectious Diseases, 39 (1). pp. 169-177. ISSN 0934-9723
Freeman, J, Vernon, J, Pilling, S et al. (5 more authors) (2018) The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011–2014. Clinical Microbiology and Infection, 24 (7). pp. 724-731. ISSN 1198-743X
Freeman, J, Pilling, S, Vernon, J et al. (1 more author) (2017) In vitro activities of MCB3681 and 8 comparators against Clostridium difficile isolates with known ribotypes and diverse geographical spread. Antimicrobial Agents and Chemotherapy, 61 (3). e02077-16. ISSN 0066-4804
Freeman, J, Vernon, J, Vickers, R et al. (1 more author) (2016) Susceptibility of Clostridium difficile isolates of varying antimicrobial resistance phenotypes to SMT19969 and 11 comparators. Antimicrobial Agents and Chemotherapy, 60 (1). pp. 689-692. ISSN 0066-4804
Crowther, GS, Chilton, CH, Longshaw, C et al. (5 more authors) (2016) Efficacy of vancomycin extended dosing regimens for treatment of simulated Clostridium difficile infection (CDI) within an in vitro human gut model. Journal of Antimicrobial Chemotherapy, 71 (4). pp. 986-991. ISSN 0305-7453
Corbett, D, Wise, A, Birchall, S et al. (8 more authors) (2015) In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. Journal of Antimicrobial Chemotherapy, 70 (6). pp. 1751-1756. ISSN 0305-7453